The lawsuits were thrown out because both insurers were considered indirect purchasers of Suboxone, voiding their standing to sue via the Racketeering Influenced and Corrupt Organizations Act, according to the court opinion.
The initial civil lawsuits from the insurers claimed Indivior schemed to get users to switch from a tablet version of Suboxone — which lost exclusivity in 2009 — to a dissolvable strip before aiming to remove the tablet from the market.
Indivior has faced its fair share of troubles over Suboxone in the past, including federal fraud charges and allegations of misleading marketing, which led to the jailing of its CEO.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
